MiNK Therapeutics, Inc. (INKT) Misses Q1 EPS by 64c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q1 EPS of ($0.70), $0.64 worse than the analyst estimate of ($0.06).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
• Ionis Pharmaceuticals (IONS) PT Raised to $130 at H.C. Wainwright
• H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)